

A

(For new non-provisional applications under 37 CFR § 1.53(b))

~~~~~

## Derrick Brown

6. ☐ Microfiche Computer Program (Appendix)

| Demographic Data |        | Health Status   |               | Healthcare Utilization |                | Healthcare Costs |           | Healthcare Access |                | Healthcare Quality |             | Healthcare Equity |         | Healthcare Innovation |          |
|------------------|--------|-----------------|---------------|------------------------|----------------|------------------|-----------|-------------------|----------------|--------------------|-------------|-------------------|---------|-----------------------|----------|
| Age              | Gender | Chronic Disease | Acute Disease | Primary Care           | Specialty Care | Medication       | Procedure | Insurance         | Transportation | Provider           | Environment | Language          | Culture | Technology            | Research |
| 18-24            | Male   | 10%             | 5%            | 15%                    | 10%            | 20%              | 15%       | 10%               | 5%             | 10%                | 10%         | 10%               | 10%     | 10%                   | 10%      |
| 25-34            | Female | 15%             | 10%           | 20%                    | 15%            | 25%              | 20%       | 15%               | 10%            | 15%                | 15%         | 15%               | 15%     | 15%                   | 15%      |
| 35-44            | Male   | 20%             | 15%           | 25%                    | 20%            | 30%              | 25%       | 20%               | 15%            | 20%                | 20%         | 20%               | 20%     | 20%                   | 20%      |
| 45-54            | Female | 25%             | 20%           | 30%                    | 25%            | 35%              | 30%       | 25%               | 20%            | 25%                | 25%         | 25%               | 25%     | 25%                   | 25%      |
| 55-64            | Male   | 30%             | 25%           | 35%                    | 30%            | 40%              | 35%       | 30%               | 25%            | 30%                | 30%         | 30%               | 30%     | 30%                   | 30%      |
| 65-74            | Female | 35%             | 30%           | 40%                    | 35%            | 45%              | 40%       | 35%               | 30%            | 35%                | 35%         | 35%               | 35%     | 35%                   | 35%      |
| 75-84            | Male   | 40%             | 35%           | 45%                    | 40%            | 50%              | 45%       | 40%               | 35%            | 40%                | 40%         | 40%               | 40%     | 40%                   | 40%      |
| 85+              | Female | 45%             | 40%           | 50%                    | 45%            | 55%              | 50%       | 45%               | 40%            | 45%                | 45%         | 45%               | 45%     | 45%                   | 45%      |
| 18-24            | Male   | 10%             | 5%            | 15%                    | 10%            | 20%              | 15%       | 10%               | 5%             | 10%                | 10%         | 10%               | 10%     | 10%                   | 10%      |
| 25-34            | Female | 15%             | 10%           | 20%                    | 15%            | 25%              | 20%       | 15%               | 10%            | 15%                | 15%         | 15%               | 15%     | 15%                   | 15%      |
| 35-44            | Male   | 20%             | 15%           | 25%                    | 20%            | 30%              | 25%       | 20%               | 15%            | 20%                | 20%         | 20%               | 20%     | 20%                   | 20%      |
| 45-54            | Female | 25%             | 20%           | 30%                    | 25%            | 35%              | 30%       | 25%               | 20%            | 25%                | 25%         | 25%               | 25%     | 25%                   | 25%      |
| 55-64            | Male   | 30%             | 25%           | 35%                    | 30%            | 40%              | 35%       | 30%               | 25%            | 30%                | 30%         | 30%               | 30%     | 30%                   | 30%      |
| 65-74            | Female | 35%             | 30%           | 40%                    | 35%            | 45%              | 40%       | 35%               | 30%            | 35%                | 35%         | 35%               | 35%     | 35%                   | 35%      |
| 75-84            | Male   | 40%             | 35%           | 45%                    | 40%            | 50%              | 45%       | 40%               | 35%            | 40%                | 40%         | 40%               | 40%     | 40%                   | 40%      |
| 85+              | Female | 45%             | 40%           | 50%                    | 45%            | 55%              | 50%       | 45%               | 40%            | 45%                | 45%         | 45%               | 45%     | 45%                   | 45%      |

7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- ☐ Computer Readable copy
  - ☐ Paper Copy (identical to computer copy)
  - ☐ Statement verifying identity of above copies
8. ☐ Assignment Papers
9. Power of Attorney
- ☐ Is attached.
  - ☐ The power of attorney appears in the original papers of the prior application.
  - ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
10. ☐ Information Disclosure Statement (IDS)
- ☐ Copies of IDS Citations
11. Amendments
- ☐ A preliminary amendment is enclosed.
  - ☐ Cancel in this application claim(s) \_\_\_\_\_ before calculating the filing fee. At least one independent claim is retained for filing purposes.
  - ☐ Amend the specification by inserting before the first line the sentence: \_\_\_\_\_.
12. ☒ Return Receipt Postcard
13. Small Entity Status
- ☐ A small entity statement is enclosed.
  - ☐ A small entity statement was filed in the prior non-provisional application and such status is still proper and desired.
  - ☐ Is no longer claimed.
14. ☒ Priority of foreign application number 0019518.0, filed on August 8, 2000 in the UK is claimed under 35 U.S.C. §§ 119(a)-(d)
15. ☐ Petition under 37 C.F.R. § 136 for Extension of Time
16. ☐ Other: \_\_\_\_\_

Address all future correspondence to:

B. Noël Kivlin  
Conley, Rose, & Tayon, P.C.  
P.O. Box 398  
Austin, Texas 78767  
Phone: (512) 476-1400 Fax: (512) 703-1250

Signature

Name

Registration No.

Date

B. Noël Kivlin

33,929

8-8-01